Advertisement NSF at Interphex 2022 in New York, 24 May - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
More info about NSF International

NSF at Interphex 2022 in New York, 24 May

The FDA’s decision to restart in-person inspections at manufacturing facilities is expected to be the main topic of conversation at Interphex 2022 as it kicks off in New York on 24 May. NSF Health Sciences will have consultants at the event to answer any questions that manufacturers or distributors might have about the agency’s resumption of activities.

Varun Venkatachalum and Phil Lynch from NSF are both working on active projects assisting companies who have just completed their inspections and require remediation and with companies who are readying their facilities.

Speaking recently about the issue, Varun Venkatachalum, Principal Consultant with NSF identified five factors that companies need to keep in mind when aiming to secure a successful inspection. They include effective management of deviations, ensuring that SOPs are updated and followed precisely, guarding against variations in human performance particularly at times with staff absences, losing knowledgeable staff to The Great Resignation, and institutionalising an internal audit programme.

Venkatachalum, along with Phil Lynch and others from the company, will be on hand to answer questions from 24 to 26 May at Stand 2829.